FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients

The Washington TimesParty-alignedCenter9 hr. ago

The U.S. Food and Drug Administration (FDA) has approved a new cholesterol-lowering pill developed by Merck, named Lipfendra. This is the first non-injectable medication that targets the PCSK9 protein, which limits the body's ability to remove cholesterol from the bloodstream. Previously, treatments targeting PCSK9 required costly injections from companies like Amgen. Merck's drug was tested in two trials involving high-risk patients already on statin therapy, showing significant reductions in LDL cholesterol—over 55% in one trial and 59% in another. Side effects were reported but were comparable to a placebo. The FDA expedited the review process, though the former FDA head who initiated this pathway recently resigned amid external pressures.

Bias read (Center): The article presents factual information about a pharmaceutical development without overtly endorsing or criticizing any political entity, ideology, or policy stance. It focuses on the scientific and regulatory aspects of the drug approval, providing balanced reporting on both the benefits and the局限

STAT NewsIndependentCenter18 hr. ago

The article discusses recent developments in pharmaceuticals, including Kalshi's plan to introduce prediction markets for betting on clinical trials and regulatory approvals, and Merck's FDA approval of a new cholesterol-lowering pill called Lipfendra. Kalshi, in partnership with AppliedXL, aims to start with conservative markets focused on Phase 3 trials and FDA approval decisions. Merck's Lipfendra has shown significant reductions in LDL cholesterol levels, potentially leading to substantial sales. The piece highlights the growing integration of prediction markets into the biopharma industry and the potential impact of new treatments on public health.

Bias read (Center): The article presents information about pharmaceutical developments and regulatory approvals without overtly favoring any political ideology. It provides balanced reporting on both the introduction of prediction markets in healthcare and the FDA's approval process, without taking a clear stance on政策或

STAT NewsIndependentCenter18 hr. ago

The article discusses recent developments in the biotechnology sector, including Kalshi launching betting markets on clinical trial outcomes and FDA approvals, a collaboration with AppliedXL, and Merck receiving FDA approval for its oral PCSK9 drug. The content highlights trends in predictive analytics within biotech and notes the significance of Merck's approval as a first-of-its-kind achievement. However, the article is primarily promotional, offering access to exclusive content for STAT+ subscribers.

Bias read (Center): The article focuses on biotech developments and regulatory approvals, which are politically relevant but not overtly biased. While it mentions Merck's FDA approval as a significant event, there is no clear ideological framing or emphasis on partisan perspectives. The tone remains neutral and factual